FDA Clears Frontera’s FT-002 for Phase II Clinical Trials in the U.S.
Boston, MA, September 23, 2024 – Frontera is excited to announce that its gene therapy product, FT-002, has been cleared by the U.S. Food and Drug Administration (FDA) for Phase II clinical trials in the U.S. This approval marks a major milestone, as FT-002 becomes the first recombinant adeno-associated virus (rAAV) gene therapy to receive […]
FDA Clears Frontera’s FT-002 for Phase II Clinical Trials in the U.S. Read More »